Antiretroviral Treatment during Pregnancy and Pregnancy Outcome

Worldwide, an estimated 2.3 million children under the age of 15 are HIV positive. The main source of infection is vertical transmission from mother-to-child during pregnancy, labor and delivery, or breastfeeding.  Antiretroviral drugs (ARVs) are effective in prevention of mother- to-child transmission of HIV (PMTCT). Currently, the World Health Organization (WHO) recommended lifelong Highly Active Antiretroviral Therapy (HAART) for all pregnant women irrespective of CD4 count or disease progression. But the potential benefit and risk of HAART for asymptomatic pregnant women with high CD4 count is not well understood. Objective: To evaluate the clinical, immunologic and obstetric outcomes of pregnant women on different antiretroviral drugs, and to assess growth of  HIV exposed uninfected infants. Methods: Retrospective cohort study by reviewing medical records of HIV positive pregnant women who had antenatal care from February, 2009 to October, 2016.. Collecting socio-demographics, weight, hemoglobin level, CD4 lymphocyte count, viral load, WHO clinical stage, mode and place of delivery, infant feeding practice, opportunistic infections, chronic illnesses, acute febrile illnesses (malaria), parity, partner HIV testing history, time of initiation and type of ARVs, obstetric outcomes, (preterm birth, low birth weight /small for gestational age, spontaneous abortion; still birth, congenital anomaly) and child HIV status at six weeks.. Infants’ weight and length from birth to 12 months will be collected. Descriptive statistics used to summarize baseline characteristics. Both linear and logistic regression model will be used to explore crude associations of different ARV drugs with clinical and obstetric outcomes. The analysis will be adjusted for relevant covariates.  Moreover, infant growth will be analyzed by mixed effect linear regression models. We will analyze data using STATA 13 software package.


  • Samarbeid med Folkehelseinstituttet
  • UiO er forskningsansvarlig

Prosjektbeskrivelse med vedlegg


  • Ja


  • Nei


REK - Ja 1 fil

Tidspunkt for anonymisering og sletting av dataene

  • Anonymisering: september 2017
  • Sletting: desember 2021

Andre godkjenninger2 filer


Jeanette H. Magnus

Ansvarlig enhet

Det medisinske fakultet



  • Ph.d.-prosjekt

Helsefaglig forskning

  • Ja


  • Ikke besvart


  • Start: februar 2015
  • Slutt: desember 2020
Logg inn for å redigere prosjekter